8-K Announcements
6Material company update
Jul 20, 2026·SEC
Material company update
Jul 1, 2026·SEC
Material company update
Jun 23, 2026·SEC
Sangamo Therapeutics faces a precarious outlook as its ZFP platform remains unable to generate consistent revenue, evidenced by a 77.6% year-over-year revenue decline in 2026Q1. The company's reliance on binary milestone payments rather than commercial sales h...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 6, 2025 | -$0.11-266.7% vs -$0.03 | $581,000-98.6% vs $40M |
Q3 2025 Aug 7, 2025 | -$0.08-14.3% vs -$0.07 | $18M-46.8% vs $34M |
Q2 2025 May 12, 2025 | -$0.14-27.3% vs -$0.11 | $6M-13.2% vs $7M |
Q2 2025 Mar 17, 2025 | -$0.11-22.2% vs -$0.09 | $8M-35.5% vs $12M |
Benchmark SGMO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sangamo Therapeutics, Inc. (SGMO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.07 | $30.66M | -0.17 | -31.57% | -310.81% | -2891.84% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — | |
| $59.03 | $5.69B | -9.12 | -89.97% | -3368.72% | -24.39% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $3.54 | $639.39M | -2.62 | 55.28% | -4613.11% | -188.27% | — |
Sangamo Therapeutics, Inc. (SGMO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sangamo Therapeutics, Inc. (SGMO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 20, 2026·SEC
Jul 1, 2026·SEC
Jun 23, 2026·SEC
Get notified when SGMO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sangamo Therapeutics, Inc. (SGMO) stock FAQ — growth, dividends, profitability & financials explained
Sangamo Therapeutics, Inc. (SGMO) reported $34.6M in revenue for fiscal year 2025. This represents a 1471% increase from $2.2M in 1999.
Sangamo Therapeutics, Inc. (SGMO) saw revenue decline by 31.6% over the past year.
Sangamo Therapeutics, Inc. (SGMO) reported a net loss of $123.3M for fiscal year 2025.
Sangamo Therapeutics, Inc. (SGMO) has a return on equity (ROE) of -2891.8%. Negative ROE indicates the company is unprofitable.
Sangamo Therapeutics, Inc. (SGMO) had negative free cash flow of $90.5M in fiscal year 2025, likely due to heavy capital investments.